CCR5 and neoplasm: CC chemokine ligand 5 (CCL5) and CC chemokine receptor 5 (CCR5) were not only the leading players in tumor progression (94, 95) but also exerted anti-tumor immunity by recruiting T cells and dendritic cells, enhancing immunotherapy responses of multiple tumors (94).